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Herpes simplex virus type 1 (HSV-1) is a linear double stranded DNA virus that is 
responsible for one of the most common sexually transmitted diseases within the United 
States. However, treatment drugs for HSV-1 could be costly and may have side effects. 
In recent years the number of cases of drug resistant HSV-1 has increased, resulting in 
interest for novel treatments. This study aimed to investigate the antiviral effects of the 
reagent Embelin on HSV-1 infection in cultured Vero Cells. Embelin is a benzoquinone 
isolated from the plant Embelia ribes. Cell viability and cell proliferation assays were 
conducted to determine the maximum noncytotoxic concentration of Embelin. Additional 
assays were conducted to measure cell proliferation and antiviral effect. The results of 
this study suggest that Embelin indeed inhibits HSV-1 with best viral inhibition between 
50 μM and 54 μM. Also, Embelin seems to be most effective at inhibiting the virus at the 
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Review of literature 
 
Classification and life cycle 
HSV-1 is a member of the family Herpesviridae, and subfamily 
Alphaherpesvirinae. Alphaherpesvirinae is special due to the rapid production and the 
quick tearing down of the host cell (Mettenleiter et al., 2008).  HSV-1 is double stranded 
DNA (dsDNA) enveloped virus that causes a wide range of infections to humans from 
mild uncomplicated mucocutaneous infections to life-threatening ones (Whitley 
and Roizman, 2001). HSV-1 has a 125-Kb linear genome that encodes for no less than 74 
genes within the genome, however overlapping transcripts, allows for as many as 84 
different proteins (McGeoch et al., 2006; Rajčáni et al., 2004).  Furthermore, the genome 
of HSV-1 contains two regions, a long region called long unique region (UL) and a short 
one called the short unique region (US). From the 74 known genes found in HSV, 54 of 
those genes are found in UL where the US contains 12 (McGeoch et al., 1988). The size 
of the virus is relatively large compared to other viruses. The dsDNA is enclosed within 
an icosahedral protein which is surrounded by a lipid bilayer (Mettenleiter et al., 
2006).  HSV-1 is one of the most successful human pathogens in terms of its worldwide 
spread and persistence in the host. HSV-1 has become a global health issue with 67% 
(estimated 3.4 billion) of the world population between the ages of 0 and 49 infected 
(Looker et al., 2015). Studies have also shown an observed increase in neonatal spread 
occurrence between 2009 and 2015 in the Medicaid population in the United States 
(Szpara et al., 2014; Mahant et al., 2019).   
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Entry of the virus involves multiple surface glycoproteins, glycoprotein B (gB), 
glycoprotein C (gC), glycoprotein D (gD), glycoprotein H (gH), and glycoprotein L (gL), 
interacting with surface receptors on the host cell. Specifically, gC and/or gB binds to 
surface particles followed by gD binding to entry receptors (Clarke, 2015; Subramanian 
and Geraghty, 2007; Stevens, 1975). However, gC is not essential for the entry of the 
virus, but lacking it decreases entry and binding of the virus to the host cell (Shukla and 
Spear, 2004). Both gB and gH show fusion characteristics, while gD does not 
(Campadelli-Fiume et al., 2007; Heldwein et al., 2006). A number of cell receptors were 
found that interact with gD. Some of these known receptors include heparan sulfate, 
nectin-1, nectin -2, and herpes virus entry mediator (Spear, 2004). After one of these 
cellular receptors binds to gD, causing a confirmation change, a glycoprotein complex 
that includes gB, gD, gH and gL forms (Tiwari and Shukla, 2010). This causes the 
mixing of the membranes followed by entry and binding of the virus to the minus end of 
the microtubule dynein (Sodeik et al., 1997). The virus then travels to the nucleus where 
it injects the viral DNA (Newcomb et al., 2007). This process occurs using a capsid portal 
made from 12 copies of portal protein (UL6) (Newcomb et al., 2007; Cardone et al., 
2007). Transcription of the HSV-1 DNA is done using the enzyme RNA polymerase II 
from the host cell (McGeoch, 2006). The first genes that are transcribed, immediate early 
genes, express proteins that regulate the synthesis of early, late and latency stage proteins 
(Adang et al., 2006). These genes are transcribed immediately following the infection 
(Murphy et al., 2008). The late genes codes for the capsid and its receptors. After 
assembly, the virus then buds out of the cell membrane forming a membrane around the 




The scope of the problem 
HSV-1 is the viral causative agent of genital and oral herpes. These are 
contagious and long-lasting infections that cause painful blisters or ulcers at the site of 
infection (McQuillan, 2018). According to the World Health Organization, approximately 
3.7 billion people or 67% of the world’s population under the age of 50 are infected with 
HSV-1, and more than 50% of adults in the United States are seropositive (Hoshino et al., 
2009). In younger females, the rate of genital HSV-1 infection has become more common 
than the rate of HSV-2 genital infection (Bernstein et al., 2013). Herpes infection most 
commonly occurs in the Americas, Europe and Western Pacific according to the World 
Health Organization. Since the virus can remain latent, it can be reactivated at any time 
well into adulthood. 
There are many cases of which a possible complication may occur. Although 
these complications might be rare, the over prevalence of the virus makes it otherwise. A 
good example is Herpes viral encephalitis, or Herpes simplex encephalitis (HSE), a form 
of encephalitis that is due to herpes simplex infection. Although both HSV-1 and type 2 
can cause this encephalitis around 90% of cases of herpes encephalitis are caused by 
HSV-1 (Bradshaw and Venkatesan, 2016). HSE has been associated with 30% mortality 
as well as severe neurological defects in treated patients with 70% mortality in untreated 
patients (Zatońksi et al., 2006). Symptoms of HSE develop over several days (Gnann and 
Whitley, 2017). Early symptoms include headaches, fevers, and seizures. More advanced 
symptoms include aphasia, anosmia as well as memory loss (McGrath et al., 1997).  
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Another complication is recurrent ocular infection. This ocular infection, also 
known as Herpetic simplex keratitis, is the leading cause of infectious blindness in 
developed countries, with around 40,000 new cases of severe visual impairment arising 
every year (Farooq and Shukla 2012). In addition, neonatal herpes is becoming more 
prevalent with around 1,500 cases of neonatal herpes being reported yearly in the United 
States, but most occur in Africa (George et al., 2014; Looker et al., 2017). Neonatal 
herpes is the cause of transmission of HSV-1 from the mother exhibiting the genital 
infection to a child during birth (Linakis and Reynolds, 2020). Finally, a study done in 
1980 has shown some link between  HSV-1 and Alzheimer’s disease (Middleton, 1980). 
HSV-1 seems to harm the nervous system and interact with components and receptors of 
lipoproteins, which may lead to the development of Alzheimer’s disease (Mosmann et al., 
2019). However, according to a study published in 1997, there seems to be no 
neurological damage or increase the risk of Alzheimer’s if the patient lacks the epsilon4 
allele of the gene APOE (Itzhaki et al., 1997). In addition, another study published in 
2008 showed a statistical difference between individuals with antibodies against HSV, 
indicating recent reactivation, and those without these antibodies in the incidence of 
Alzheimer’s disease (Letenneur et al., 2008). Yet, it is worth noting the patients studied 
had no antibody at baseline making the result open to question. Another study done in the 
United Kingdom showed that treating HSV1-infected cells with antiviral drugs decreased 
the accumulation of β-amyloid and tau proteins that are linked to Alzheimer’s disease 
(Wozniak et al., 2011). Finally, a more recent 2018 retrospective study from Taiwan 
conducted on 33,000 patients with HSV-1, showed that HSV-1 infection increased the 
risk of dementia 2.56 times for the untreated patients and no elevated risk of dementia for 
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the treated ones (Tzeng et al., 2018). This high prevalence and complications associated 
with the virus indicates the scope of the problem and the amount of attention it requires.   
Herpes virus is transmitted by contact with an infected person who has 
reactivation of the virus (Dobson and Itzhaki, 1999). Also, asymptomatic reactivation 
may occur in which the virus causes atypical, hard to notice, or minute symptoms that are 
not identified as an active herpes infection or disease; therefore, acquiring the virus is 
possible even if no active HSV blisters or sores are present (Cohrs et al., 2008). The 
infection of HSV-1 can be active (lytic), or dormant (lysogenic) (Placek et al., 2010). The 
reactivation of HSV-1 can be due to either stress, immunosuppression, radiation or even 
heat (Halford et al., 1996). When the reactivation is triggered in some way, the virus will 
travel along the neuronal axon and re-infect the epithelial cells. This process of dormant 




There is no cure for Herpes simplex virus. The most common treatment of HSV-1 
involves acyclovir which is a nucleoside analog, its derivatives and their respective 
prodrugs, valacyclovir and famciclovir (James et al., 2014; Tyring et al., 2000). These 
drugs function as DNA chain terminators by targeting DNA polymerase and therefore, 
they decrease viral propagation by the suppression of viral replication (Piret and Boivin, 
2011). 
The ability of the virus to exist in the latent stage reveals the inefficiency of these 
treatments (Agelidis and Shukla, 2015). In addition, the virus can easily gain resistance to 
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these types of drugs (Liang et al., 2018). Lastly, there is a noticeable increase in the 
global load of HSV-1 rather than a decrease, shedding light on the need for additional 
treatment strategies (Durukan et al., 2019). Therefore, there is an urgent need for new 
treatments against the virus. 
In recent years, there has been a strong effort in developing an HSV vaccine 
(Royer et al., 2015). These efforts have focused mainly on recombinant viral proteins, 
attenuated viral candidates and hybrid recombinant viruses (Sandgren et al., 2016). Many 
vaccines have been developed, starting from the 1920s, yet none has been successful to 
this day (Alami Chentoufi et al., 2012). A successful vaccine should induce immune 
responses adequate to prevent infection, prevent colonization of the ganglia or at 
least reduce the frequency or severity of recurrences of viral episodes (Sandgren et al., 
2016). Due to the high genetic similarity of both herpes simplex virus type 1 and 2 
(Lasky and Dowbenko, 1984), a prophylactic or therapeutic vaccine that is effective 
against one type could also prove to be effective against the other.  
There are many vaccines in clinical trials (Denes et al., 2020). However, there are 
multiple reasons and contributing factors for the failure to develop successful vaccines. 
One of those reasons is the fact that Herpesvirus is able to evade many features in the 
human immune response (Su and Zheng, 2016). The subunit vaccines which use small 
groups of viral antigens are promising. However, these are generally limited to producing 
humoral immunity (Ashley et al., 1985). Attenuated vaccines and replication-defective 
vaccines can produce both cellular and humoral immunity (Nguyen et al., 1992). 
However, they proved challenging to produce at scale offering limited immunization 
(Arvin et al., 2007).  
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Another very important contributing factor in the partial failure of recent vaccine 
trials, is the wide genetic variation in strains of HSV-1 (Szpara et al., 2014). An 
important target for vaccines is the viral glycoprotein B. This has been the target for 
many vaccination studies due to it being a prominent antigenic site. Its first 80 amino 
acids sequence acts as a binding site for MHC II proteins on antigen-presenting 
cells (Sievers et al., 2002). Yet, some studies have shown that these sites are highly 
variable sites, explaining the challenges present in the production of vaccines (Szpara, et 
al., 2014). Alternative treatments such as microbicide and specifically those of natural 
products seem promising. In recent years, research has shown that natural products can 
exhibit remarkable antiviral activity (Li et al., 2018; Asai and Nakashima., 2018).   
 
Natural products 
Natural products have been and continue to be a vital source of medical 
treatments. These natural products are very important because they allow for economic 
and environmentally friendly production minimizing the harmful toxins and by products 
(Ji et al., 2015). The vast majority of current medicines are either directly obtained 
natural products or derived (Atanasov et al., 2015). More importantly in this case, a large 
spectrum of antivirals has been isolated from fruiting bodies and filtrates of various 
biological plants and mushrooms (Pradeep et al., 2019). In addition, many biological 
plant based compounds have been demonstrated to hold activity against HSV-1 (Hassan 
et al., 2015). There have been many discoveries in recent years highlighted by plant 
based compounds such as curcumin, resveratrol,  pomegranate rind extract, Cornus 
canadensis extract, and extracts from Camellia sinensis, epigallocatechin gallate 
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(EGCG), palmitate-epigallocatechin gallate (P-EGCG) and epigallocatechin gallate -
stearate  (EGCG-S) against HSV-1.  
Curcumin, the main bioactive compound in turmeric, has shown antiviral activity 
against HSV-1 (Zandi, 2010; Flores et al., 2016). Resveratrol, the main bioactive 
compound in red wine (Annunziata et al., 2018). In several studies done in vivo, 
resveratrol significantly reduced lesions in a dose, start of treatment time, and number of 
applications dependent manner (Docherty et al., 2004; Docherty et al., 2005). It has been 
reported that 30 μM of curcumin reduces the production of both HSV-1 and HSV-2, this 
occurs through interfering with the adsorption step of the viral cycle (Flores et al., 2016). 
Other compounds such as Punicalagin and ellagic acid, which are the active compounds 
in pomegranate rind extract, have presented antiviral activity against HSV-1. 
Hydrolysable tannins have also shown some antiviral effects against HSV-1 (Houston et 
al., 2017). Hydrolysable tannins are the active chemical in Cornus canadensis extract. 
Studies demonstrated that at a concentration of 100 μg/mL HSV-1 is inhibited in both the 
replication and absorption steps (Lavoie et al., 2017). 
Crude extracts have been shown to obtain some antiviral activity encompassing 
anti- HSV-1 activity (Schnitzler et al., 2010). For example, various studies have shown 
that the resin collected by bees from plants (propolis) has shown promising inhibitory 
activities. It has shown over 50% inhibition in vitro studies and 80-85% inhibition in vivo 
(Huleihel and Isanu, 2002). It has been suggested that the presence of polyphenols, 
flavonoids and phenyl carboxylic acid are the reasons for the inhibition activity 
(Schnitzler et al., 2010). 
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EGCG is one of the four polyphenols present in green tea reported to have many 
biological activities including antioxidant and anticancer (Wolfram, 2007). EGCG has 
been shown to process many antiviral activities against a wide range of viruses (Vázquez-
Calvo et al., 2017)  From these, EGCG has shown to inhibit both HSV-1 and HSV-2 
(Calland et al., 2012). However, EGCG is not stable. A modified EGCG has shown some 
very promising results against HSV-1. For example, digallate dimers of EGCG have been 
shown to inhibit HSV-1 under 100 μM concentration (Isaacs et al., 2011). A more stable 
form of EGCG, EGCG-S, inhibits the HSV-1 (Paschalis, 2019). Finally, P-EGCG also 
inhibits the virus at concentrations of 50 μM and higher (De Oliveira et al., 2013).  
It is important to continue to search for novel antiviral compounds due to the 
ability of the virus to develop resistance to therapeutics (Robert et al., 2014). It is 
especially important because the virus infects different cell types in humans. Embelin a 
novel compound has shown some promising biological activities including anticancer, 
anti-inflammatory, and antibacterial (Kumar et al., 2017). Minimal work has been done 
on its antiviral effects and no studies have been done on HSV-1 (Pullaiah, 2002). 
 
Embelin 
Embelin ( 2,5-dihydroxy-1,4-benzoquinone ) is a benzoquinone derivative that 
exhibits anxiolytic, anti-inflammatory activity, antioxidant, anticonvulsant, 
antidepressant, anthelmintic, antimicrobial, anticancer and many more biological 
activities (Kumar et al., 2017). Embelin is an orange solid derived from the plant Embelia 
ribes found throughout India. It is not water soluble; however, it can dissolve in organic 
solvents. Embelin is not evaluated as a hazardous substance (Radhakrishnan and 
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Gnanamani, 2014). Many animal experiments have shown no significant changes in 
behavioral or physical appearance upon Embelin treatment in small dosage (Prakash et 
al., 1994). Additionally, Embelin has been shown to have a high therapeutic index (as 
high as 200mg/Kg) in some studies (Gupta, 1991).  
Embelin is known for its anticancer activity (Xu et al., 2005). It has been shown 
that it can act on caspase proteins to induce apoptosis (Joy et al., 2010). Also, it can 
improve the function of the liver and act as an antioxidant (Singh et al., 2009). Embelin 
has shown some analgesic effects as an anti-inflammatory (Chitra et al., 1994).  Embelin 
is considered to be a good candidate for treating skin diseases as well as respiratory 
disorders, helminthiasis and gastrointestinal disorders as well as improving immune 
functions and blood circulation (Poojari, 2014; Kumar, et al., 2011). 
Embelin has been studied as an antibacterial agent. In one study, it has been 
shown to have a significant reduction against Staphylococcus aureus, Streptococcus 
pyogenes, Shigella flexneri, Shigella sonnei and Pseudomonas aeruginosa (Chitra, et al., 
2003). A more recent study has shown that Embelin provides promising antibacterial 
activity against some Gram-positive bacteria and bacteriostatic activity against Gram 
negative ones (Radhakrishnan, et al., 2011). Although many studies have focused on its 
antibacterial effects, minimal studies have been done on its antiviral properties. A 
previous study has shown some antiviral activity against different strains of influenza 
virus (Parvez et al., 2019). In that study, several compounds were studied and Embelin 
was the most prominent antiviral against the influenza virus. It showed a selectivity index 
(SI) of 32 in the influenza virus A/Puerto Rico/8/34 (H1N1) strain. SI is the ratio of 
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availability concentration over antiviral effects (Flamand et al., 2014). Also, it showed an 
SI of 31 against A/mallard/Pennsylvania/10218/84 (H5N2) and 5 against A/Aichi/2/68 
(H3N2) virus. In another study examining the hepatitis B virus, Embelin showed over 
60% inhibition (Parvez et al., 2019). 
            Due to its bioactivity and safe consumption, Embelin is an ideal antiviral 
compound to examine its potential as a novel therapeutic treatment to inhibit HSV-1. The 




Materials and Methods 
Cell Culture 
Vero cells, derived from the kidney of an African green monkey, were kept in 
Dulbecco's Modified Eagle Medium (DMEM) and supplemented with 5% fetal bovine 
serum (Serum Source International) and 1% gentamicin sulfate (10 mg/mL, 
BioWhittaker), and incubated at 37 °C and 5% CO2. Cell culture was done in T25 flasks 
(25cm2), 6-well plates (9.5cm2) and 96-well plates (0.32cm2). The cells were incubated 
until 70-80% confluency was reached. This was followed by infection and treatment. A 
Biostar inverted microscope (Reichert) was used through all experiments requiring light 
microscopy. 
 
Preparation of virus 
A recombinant strain of HSV-1, GHSV-UL46 (ATCC VR-1544), was used in all 
the experiments performed. This strain is labeled with green fluorescent protein through 
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fusion of GFP to the structural tegument protein VP11/12 (Willard, M., 2002). Virus 
stocks were prepared by infection of a flask of Vero cells for one hour at 37 °C and 5% 
CO2, followed by aspiration of the unabsorbed virus with the media. When cytopathic 
effect was seen, the contents of the flask were harvested and centrifuged at low speed for 
5 minutes. The supernatant containing purified virus was aliquoted into 1.5 mL cryogenic 
tubes and stored at -80 °C.  
 
Embelin 
Purified Embelin (generously donated by Dr. M. Rossi, Vassar College, 
Poughkeepsie, NY) was obtained as an orange compound and dissolved in DMSO to 
prepare 10mM stock. Concentrations ranging from 10 μM to 70 μM were made as 
necessary using DMEM and were stored at  4 °C. 
 
Cytotoxicity assays 
To examine the cytotoxicity of Embelin on the cells, Vero cells were cultivated 
for 24 hours in a 6-well plate until 70-80% confluent. Then, increasing concentrations of 
Embelin were added ranging from 10μM to 70μM. After 1 hour of incubation, the 
solution was aspirated, and fresh media was added. Fresh media was also added to empty 
wells as a blank. Then the cells were observed using an inverted microscope. For 
quantitative analyses, a CellTiter 96 AQueous Cell Viability Assay (Promega) was 
utilized in a 96-well plate. This assay measures cell viability by the reduction of MTS 
tetrazolium to formazan, where absorbance of 490 nm is related to cell count. To perform 
this assay, 20μL of the MTS/PMS solution were added to the existing media in each well 
as per manufacturer’s directions, and the plate was incubated at 37 °C and 5% CO2 for 
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one hour. The absorbance was measured using 2000 PRO microplate reader (Tecan). Cell 
viability for each treatment condition was then calculated using the following formula: % 
Viability = [(Treated cells - Blank)/(Cells only - Blank)]*100%. Standard deviation was 
calculated using excel function 
 
Antiviral assay 
To determine Embelin’s antiviral effects on HSV-1, Vero cells were cultivated for 
24 hours in a 6-well plate until 70-80% confluent. Embelin treated virus was added to the 
cells. The virus was treated with increasing concentrations of Embelin up to 54μM. Then, 
one-hour post infection, any unabsorbed virus media was aspirated and replaced with 
DMEM. Cells were incubated at 37°C and 5% CO2. After 48 hours, the cell viability was 
measured using the CellTiter 96 AQueous Cell Viability Assay (Promega) as described 
above. In addition, a viral ToxGlo ATP Detection Buffer (Promega) assay was done. 
100μL was added to the cells and the plate was allowed to incubate for 15 minutes as per 
manufacturer’s directions. A 2000 PRO microplate reader (Tecan) was used.  Cell 
viability was then plotted against HSV-1 treatment using the following equation: % 
Viability = [(Cells infected with treated HSV-1 - Blank)/(Cells only - Blank)]*100%. 
Standard deviation was calculated using excel function. 
 
Binding assay 
Vero cells were grown for 24 hours in a 96-well plate, until 70-80% confluent. 
The plate was pre-incubated at 4 °C for 30 minutes. Subsequently, the media was 
removed from the cells. Treated and untreated HSV-1virions were incubated at room 
temperature of one hour followed by infection of the cells on ice. The virus was treated 
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with increasing concentrations of Embelin to 54μM. The plate was incubated for 1 hour 
at 4 °C, then unbound HSV-1 was carefully aspirated from the cells using a multichannel 
pipette. Fresh media was added to each well. The plate was incubated at 37 °C and 5% 
CO2 for 48 hours and assayed using the Viral ToxGlo assay.  
 
Penetration and post penetration assay 
Vero cells were cultivated in a 96-well plate, until 70-80% confluent. Then the 
media was removed from the cells and infected with 100μL of HSV-1.  The plate was 
incubated at 4 °C for 2 hours, to ensure attachment but not penetration of the HSV-1. 
Then, at room temperature, various concentrations of Embelin were added. The plate was 
incubated at room temperature for 10 minutes for penetration assay and 30 minutes for 
post penetration assay (Harden et al., 2009). This was followed by the addition of 100 μL 
of 1X phosphate buffer saline (PBS) (pH 3.0) to each well to inactivate the virions. Then, 
the media was removed carefully using a multichannel pipette followed by the addition of 
100 μL of fresh 5% FBS DMEM. Finally, after 48 hours, viability was determined using 
the Viral ToxGlo ATP Detection Buffer (Promega) assay. The plate was read using the 
Infinite 2000 PRO microplate reader (Tecan).  
 
Fluorescent microscopy 
To prepare cells for microscopy, the cells were grown on glass cover slips in 6-
well plates. Vero cells were incubated at 37 °C and 5% CO2 until 70-80% confluent. 
When confluent, the cells were infected with treated HSV-1. The virus was treated with 
54μM of Embelin for one hour. Uninfected cells served as a negative control. Untreated 
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virus served as positive control.  After one hour of infection the media was aspirated, and 
new media was added. Then the cells on the slip were prepared and fixed 8 hours post 
infection (hpi), and 12 hpi. First, the cells were treated with 300μL of DAPI (4,6 - 
diamidino - 2 - phenylindole) stain for 5 minutes at 37°C in the dark. Then, the cells were 
fixed using 2-4% paraformaldehyde for 10-20 minutes followed by PBS wash. Then 
mounting medium was used to fix coverslip on the slide. The mounting medium solution 
contained 90% glycerol and 10% PBS.  The slides were observed using Zeiss Axio Scope 
A1 microscope in the dark. The images were merged using imageJ software. 
 
Quantitative polymerase chain reaction (qPCR) 
To prepare for qPCR, the cells were grown in a 6-well plate at 37 °C and 5% CO2 
until 70-80% confluent. Then, the cells were infected with treated HSV-1. The virus was 
treated with 54μM of Embelin for an hour. Uninfected cells served as a negative control. 
Untreated virus served as positive control.  After 30 minutes of infection the media was 
aspirated, and new media was added. 12hpi the DNA was collected using Dneasy blood 
& tissue kit (QIAGEN). PCR followed by gel electrophoresis was performed to confirm 
the presence of viral DNA. The primers HSV1 gD forward 5´-
CAACCCTACAACCTGACCATC-3´ and HSV1 gD reverse 5´-
TTGTAGGAGCATTCGGTGTAC-3´ were used. Then qPCR was performed using 
Applied Biosystems™ SYBR™ Green PCR Master Mix on 96-well plate MicroAmp™ 
Optical 96-Well Reaction Plate. Also, a 10-fold serial dilution was done up to the 10-5 
dilution in order to determine the standard curve equation and R2. This calculation was 








Cytotoxicity Study of Treatment of Vero cells with Embelin 
The cytopathic effects of Embelin and DMSO were determined by treatment of 
these cells with increasing concentrations up to 60uM of Embelin and 2% of DMSO. The 
qualitative assessment was established, by determining the morphology of the cells 
through inverted microscope imaging. Cells treated with up to 60μM showed no signs of 
morphological change and the cell monolayer was intact. This was compared to the cells 
only control (Figure 1 a). The effects were quantified through the MTS assay. The cells 
were grown in a 96-well plate and incubated for 1 hour with increasing concentrations of 
Embelin. The assay was performed after 56 hours of incubation and absorbance was 
measured at 490 nm which directly correlates with cell viability. Percent viability ranged 
from a low of 84.21% at 50 μM to 100% for 54 μM concentrations (Figure 1b). This 
difference might be due to the nature of the assay reading with a small number OD. 
Calculation was performed using % Viability = [(Cells infected with treated HSV-1 - 
Blank)/(Cells only - Blank)]*100%. The bars demonstrate the standard deviation was 
calculated using excel function. This demonstrates the Embelin does not exert toxic 












Figure 1: (a) presents the viability of Vero cells with Embelin treatments 
at  60μM.  Images were taken through a Biostar inverted microscope (Reichert) following 
48 hrs incubation at 37 °C and 5% CO2. Left images show cells only where the 
morphology of the cells shows a healthy, intact monolayer. Middle image shows no 
change in morphology of the Vero cells even after 60μM of Embelin treatment after 
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48hours. Right image shows the administration of 2% DMSO presenting no toxicity for 
the vehicle solution. (b) Displays cell viability after increasing concentration of Embelin 
treatment after 56hours. The error bars demonstrate the standard deviation calculated 
through excel function. Cell viability was calculated in relation to absorbance through % 
Viability = [(Cells infected with treated HSV-1 absorbance - Blank absorbance )/(Cells 
only absorbance - Blank absorbance)]*100%; where Blank absorbance is the media only 
samples. 
 
Antiviral effects of Embelin on HSV-1 
To demonstrate the antiviral effects of Embelin on HSV-1, the virus was treated 
with Embelin for 1 hour then the virus was allowed to infect the cells. Increasing 
concentrations of Embelin was administered where 54μM was the most effective (Figure 
2a right). Untreated HSV-1 (positive control) results in rounding and lifting of the Vero 
cell monolayer (Figure 2a left). The data demonstrated dose-dependent antiviral effects 
with the highest inhibition at 54μM (Figure 2b). This concentration had 102.5% cell 
viability. This means that it had slightly higher absorbance than the cell only sample. 
Then, percent inhibition was calculated from the formula = 100 x [1 - (Embelin treatment 
- cells only)/ (cells only - no treatment)]. The percent inhibition reached over 
100% inhibition with the 54μM sample and 68% with the 50μM treatment (Figure 
2c).  Then to confirm this observation, the procedure was performed again using Viral 
ToxGlo ATP Detection Buffer (Promega). The results, consistent with the previous 
observations, showed 54μM to have the highest cell viability (Figure 2d). This was done 
through measuring the luminescence 48hpi. No significant difference was seen at the 
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54μM treatment unlike the rest. Significance was calculated using the student T test 
function in Excel. Percent inhibition was calculated for each concentration of Embelin 
(Figure 2f). The highest inhibition was observed through the 54μM treatment at over 98% 
inhibition followed by 74% at the 50μM concentration. This also suggested the presence 
of dose-dependent inhibition.   




















Figure 2: (a) Presents the antiviral activity of Embelin after 48 hpi. The cytopathic effect 
(left) can be seen after HSV-1 infection of Vero cells. 54μM treatment of HSV-1 (right) 
indicated no appearance of cytopathic effect. (b) Cell viability after CellTiter 96 
AQueous Cell Viability Assay (Promega) was utilized 48hpi. This demonstrated dose-
dependent inhibition with cell viability increasing with increasing concentration of 
Embelin. (c) The percent of antiviral inhibition of Embelin concentrations on HSV-1, 
54μM treatment had the highest with 100% inhibition. (d) Viral ToxGlo ATP Detection 
Buffer (Promega) showed the luminescence of different viral Embelin treatment at 48hpi. 
(e) The percent inhibition after Embelin treatment. Consistent with previous data, 54μM 










Inhibition of binding by Embelin 
To investigate the antiviral activity of Embelin on the binding step of the viral 
cycle, HSV-1 was treated at increasing concentrations of Embelin and then used to infect 
the Vero cells for 1 hour at 4 °C. This will allow for the binding to occur but not the 
penetration of the virus. After 48 hpi, luminescence detection was done through the Viral 
ToxGlo Assay (Promega). This demonstrated, unlike the previous studies, no clear 
pattern in inhibition (Figure 3 a). Yet, there were clear signs of inhibition when antiviral 
activity was calculated with the lowest having 80% inhibition (Figure 3b). This indicates 
that Embelin inhibits the binding stage of HSV-1 infection cycle. 










Figure 3: The antiviral effects of Embelin on the binding step of the viral cycle. (a) 
Luminescence measurements of Embelin treated virus infection. The error bars represent 
the standard deviation which were determined through the STDEV.S function in Excel 
(b) Demonstrates the percent inhibition of the virus by Embelin at different 
concentrations. The percent inhibition ranged from 80.93 at 40 μM concentration of 
Embelin to 104.56 percent inhibition at 20μM concentration of Embelin.  
 
Inhibition of penetration by Embelin 
In order to determine the antiviral effects of Embelin at the time point of 
penetration of the virus into the host cell, a 96-well plate of Vero cells were infected with 
HSV-1 at 4 °C for 2 hours, to ensure attachment but not penetration of the HSV-1. Then a 
treatment of 10 minutes was performed at varying concentrations of Embelin at room 
temperature, during the penetration step. After the addition of 100 μL Viral ToxGlo ATP 
Detection Buffer (Promega), Luminescence was measured.  Dose dependent effects were 
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observed (Figure 4a). Luminescence, which is correlated with cell viability, increased as 
Embelin concentration increased. Highest cell viability occurred when HSV-1 was 
treated at 54μM and 56μM concentrations, with no significant difference determined 
between these and the control. When the antiviral activity was calculated, 54μM and 
56μM treatments had the highest percent inhibition reaching over 97% and 94% 
respectively (Figure 4b). This demonstrates that Embelin has antiviral activity in the 
penetration step of the viral cycle. The data indicated that treatment of HSV-1 with 
Embelin antiviral activity during the binding stage (Figure 3a and b) as compared to the 











Figure 4: The antiviral effects of Embelin on the penetration step of HSV-1. (a) Displays 
the results of the luminescence measurement determined by the Viral ToxGlo ATP 
Detection Buffer assay (Promega) 48hpi.  Standard deviation of four wells were 
calculated and corrected by subtracting the blank signal; where the error bars represent 
that deviation calculated through STDEV.S function in Excel. (b) The antiviral percent 
inhibition of Embelin. 
 
Inhibition of post penetration by Embelin 
The antiviral effects of Embelin on the post penetration step of the viral cycle was 
determined through infection of Vero cells in a 96-well plate. After confluency was 
observed, the cells were infected with HSV-1 at 4 °C for 2 hours, to ensure attachment 
but not penetration of the HSV-1, then treated after 30 minutes of incubation 37 °C to 
ensure that the virus had entered the cell. Then, 48hpi, the luminescence was measured 
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following the addition of 100 μL Viral ToxGlo ATP Detection Buffer (Promega). The 
results indicated that treatment with Embelin did not affect viability after the virus was 
allowed to enter the cells (Figure 5).  
    Figure 5: 
 
Figure 5: Presents the antiviral effects of treatment of HSV-1 with concentrations of 
Embelin ranging from 20μM to 54 μM post-penetration. Positive control represents no 
treatment. DMSO represents the vehicle control up on 2% administration of DMSO.  
 
Fluorescence microscopy 
The HSV-1 strain contains GFP fusion to the structural tegument protein 
VP11/12. This enabled visualization of the effects of treatment of HSV-1 with Embelin 
through fluorescent microscopy 8hpi and then 12hpi. Infected cells were visualized with 
fluorescent microscope (Figure 6). Separate images were taken of GFP and DAPI and 
merged using imageJ. GFP (green) represents the virus and DAPI (blue) represents the 
nucleus of the host cells.  It is noticeable that there is a minor decrease in the amount of 
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GFP in the no treatment image compared with the Embelin-treated HSV-1 at 8hpi (Figure 
6a). However, there is a greater difference in the expression of GFP between the 




Figure 6: Fluorescent microscopy images of Vero cells only (left), HSV-1 infected cells 
(middle) and HSV-1 treated with 54μM Embelin (right). Viral particles with GFP appear 
green and the Vero cell nuclei are blue. (a) Images taken of the cells 8hpi and (b) images 





Quantitative Polymerase Chain Reaction (qPCR) 
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In order to further investigate the antiviral effects of Embelin on HSV-1, qPCR 
Vero cells were cultivated in 6-well plates followed by infection once confluent. The 
DNA was extracted and analyzed by PCR to confirm the presence of the viral DNA (data 
not shown) and qPCR. The number of and viral particles were measured through 
calculation from the standard curve after 10-fold serial dilution and mathematical 
analysis (Figure 7a). These calculations lead to the number of viral particles present in 
treatment condition in contrast to no treatment condition (Figure 7b). The treatment of 
HSV-1 by Embelin resulted in a decrease in the viral particles 12hpi. It is important to 
note that these numbers represent the estimated number of viral particles that managed to 
enter the cells. The media was removed after the infection and only the DNA inside the 
cells were collected. To further investigate, the percent inhibition was calculated to 
compare Vero cells only and untreated HSV-1. The inhibition reached 96% just as was 













Figure 7: (a) Standard curve of the 
qPCR calculated from the CT value 
of the different dilutions. Y=mx+b 
equation of the line was calculated 
using Excel so is the R2 value. (b) 
Demonstrate the number of particles 
in the no treatment control compared 
to non-treated control.  
 
Discussion and Conclusions 
 
HSV-1 is a double stranded enveloped DNA virus that causes oral and genital 
herpes (Whitley et al., 2001). Currently there is no cure for HSV-1 although nucleoside 
analog antivirals such as acyclovir are available that shorten the span of symptoms 
(James et al., 2014; Tyring et al., 2000). Additionally, there is no vaccine available, and 
establishing one has been highly difficult (Kuo et al., 2014). Therefore, discovering a 
novel drug that could present some antiviral properties against HSV-1 is of necessity. 
Natural products have shown many antiviral properties. Embelin is a novel medicinal 
compound that has shown some incredible biological activity (Kumar et al., 2017). 
However, there are minimal studies that examined the antiviral effects against viruses 
with none that has examined effects on HSV-1. Therefore, this study focused on the 
investigation of the effects of Embelin treatment on HSV-1 infection and then further 
30 
 
investigated the inhibition at various stages of the viral cycle. Finally, the data was 
further supported using both fluorescent microscopy and qPCR. 
In this study, it was determined that Embelin has no toxic effects on the cell up to 
70μM (Figure 1b). This finding aligned with previous studies that presented Embelin as a 
safe compound that can be used up to 200mg/Kg (Mahendran et al., 2011). Therefore, 
there was no need to examine the maximum amount of Embelin that could be used since 
it was determined from this study and previous studies that a high concentration of this 
compound can have no toxic effects. Also, the goal of identifying an antiviral therapeutic 
is to find the lowest inhibitory concentration.  Qualitative antiviral effects were observed 
using microscopy at concentrations as low as 20μM, followed by further quantitative 
support from both the MTS and Tox-Glo assays. Inverted microscopy revealed the 
cytopathic effects of the virus on the cells and the effect of viral treatment with Embelin 
(Figure 2a). When the MTS assay was performed, the treated sample demonstrated 102% 
cell viability (i.e. had more signal than the cells only control) (Figure 2b). When the 
percent inhibition was calculated, in both the MTS and Tox-Glo assays, the percent 
inhibition was the highest at 54μM calculated at 102% and 98.7%, respectively (Figure 
2c and e). The results demonstrated that Embelin indeed has antiviral activity and it 
inhibited the viral infection in a dose dependent manner. However, a large difference in 
the inhibitory activity was observed with the small difference in concentration of 4μM. 
When comparing inhibition caused by treatment with 50μM and 54μM the percent 
increased by 25 - 30% in both the MTS and the ToxGlo assays consistently. It is not clear 
why this might occur. A possible reason might be due to its ability to disrupt the 
membrane (Hu et al., 2011). This was observed in a previous study on antimicrobial 
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cationic peptides, which usually affects the membrane, on HSV-1 (Albiol Matanic and 
Castilla, 2004). In the study, a similar pattern to Embelin was observed. The percent 
inhibition increased at specific concentrations. However, studies need to be done to 
further investigate this hypothesis of the action of Embelin on the membrane of HSV-1.   
To further understand how Embelin might inhibit the virus, the compound was 
administered at various points of the viral infection cycle. Embelin had the highest 
percent of inhibition when administered at the binding stage of the viral cycle (Figure 
3b). Although there was no dose dependent pattern or inhibition pattern, it is a promising 
finding since the lowest percent inhibition had over 80% at 40μM treatment. The 
penetration assay demonstrated a dose dependent pattern, (Figure 4b) yet had less 
inhibition compared to the binding step administration. However, the inhibition was still 
promising, reaching over 97% in the 54μM treatment. Also, there was an over 35% 
increase in inhibition between the 50μM and the 54μM treatment. This was consistent 
with the data from previous assays. When the virus was allowed to enter the cell, there 
was minimal to no difference between treatment and no treatment (Figure 5). This was 
consistent with previous antiviral assays that allowed the virus to enter the cell and then 
was visualized under the microscope (images not shown). There was no difference when 
visualized, where the cytopathic effects were still present even after treatment. These data 
demonstrate that Embelin is most effective at binding and penetration stages. However, 
when the virus is allowed to enter the cell, there is no observed inhibition. 
To further support these data, the effects were visualized with fluorescence 
microscopy. Images were taken after the slides were fixed at 8hpi and then 12hpi. In the 
8hpi treatment the virus expression (green) is reduced after Embelin treatment (Figure 
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6a). In the 12hpi, viral expression can also be seen to decrease (Figure 6b). When 
comparing (a) and (b) in Figure 6, there appears to be more expression in 12hpi as 
expected in both treated and non-treated assays due to the amount of time the virus was 
allowed to replicate in Vero cells. However, the reduced amount of virus in the treated 
sample as compared to non-treated is apparent.  
Finally, a qPCR was performed to further demonstrate the antiviral activity of 
Embelin on the virus. DNA extraction was performed at 48hpi. The viral particles were 
calculated by determining the number of stock viral particles followed by 10-fold serial 
dilution of the stock up the 10-5.  Then the number of viral particles in treatment and 
control were determined from the equation y=mx+b (Figure 7a). This indicated over 7 
million particles to be found in the no treatment condition inside the cell and around less 
than 300,000 when HSV-1 was treated with Embelin (Figure 7b). This showed 96% 
percent inhibition when compared with the negative and positive control. Embelin could 
be blocking the virus from entering the cell (as demonstrated in the binding and 
penetration assays) reducing its propagation to a large level. Therefore, the reason for the 
lower DNA count in treatment is not because Embelin could have blocked DNA 
synthesis of the virus, but rather Embelin inhibited the entry of the virus. Yet, this needs 
to be further supported by other studies and experiments. 
Overall, this study shows that Embelin inhibits HSV-1 in cultured Vero cells. 
Embelin is most effective in the binding step of the viral cycle followed by penetration. 
Embelin had the greatest inhibition in concentrations above 50μM 
concentration.  Embelin did not seem to have any effects against the virus once it entered 
the cell. This indicates a possible mechanism by which Embelin could inhibit the virus. 
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Although this study demonstrated these findings through multiple means, further studies 
are suggested, including a possible study of how Embelin might affect the membrane of 
the virus. Also, investigate the effect of longer treatment times for the cells at lower 
concentrations of Embelin. Finally, the antiviral effects of Embelin on naked membrane-
less viruses should be carried out as well as in vivo studies. 
Overall, this study demonstrated that Embelin has antiviral effects against HSV-1 
in cultured Vero cells. This could lead to an effective therapeutic treatment to reduce the 





























Adang, L. A., Parsons, C. H., & Kedes, D. H. (2006). Asynchronous progression 
through the lytic cascade and variations in intracellular viral loads revealed by high-
throughput single-cell analysis of Kaposi's sarcoma-associated herpesvirus infection. 
Journal of virology, 80(20), 10073-10082. 
Agelidis, A. M., & Shukla, D. (2015). Cell entry mechanisms of HSV: what we 
have learned in recent years. Future virology, 10(10), 1145-1154. 
Alami Chentoufi, A., Kritzer, E., Yu, D. M., Nesburn, A. B., & BenMohamed, L. 
(2012). Towards a rational design of an asymptomatic clinical herpes vaccine: the old, 
the new, and the unknown. Clinical and Developmental Immunology, 2012. 
Albiol Matanic, V. C., & Castilla, V. (2004). Antiviral activity of antimicrobial 
cationic peptides against Junin virus and herpes simplex virus. International Journal of 
Antimicrobial Agents, 23(4), 382–389. doi: 10.1016/j.ijantimicag.2003.07.022 
Annunziata, G., Maisto, M., Schisano, C., Ciampaglia, R., Narciso, V., Tenore, G. 
C., & Novellino, E. (2018). Resveratrol as a novel anti-herpes simplex virus nutraceutical 
agent: An overview. Viruses, 10(9), 473. 
Arvin, A., Campadelli-Fiume, G., Mocarski, E., Moore, P. S., Roizman, B., 
Whitley, R., & Yamanishi, K. (Eds.). (2007). Human herpesviruses: biology, therapy, and 
immunoprophylaxis. Cambridge University Press. 
35 
 
Asai, D., & Nakashima, H. (2018). Pathogenic viruses commonly present in the 
oral cavity and relevant antiviral compounds derived from natural products. Medicines, 
5(4), 120. 
Ashley, R., Mertz, G., Clark, H., Schick, M., Salter, D., & Corey, L. (1985). 
Humoral immune response to herpes simplex virus type 2 glycoproteins in patients 
receiving a glycoprotein subunit vaccine. Journal of virology, 56(2), 475-481. 
Atanasov, A. G., Waltenberger, B., Pferschy-Wenzig, E. M., Linder, T., 
Wawrosch, C., Uhrin, P., ... & Rollinger, J. M. (2015). Discovery and resupply of 
pharmacologically active plant-derived natural products: A review. Biotechnology 
advances, 33(8), 1582-1614. 
Bernstein, D. I., Bellamy, A. R., Hook III, E. W., Levin, M. J., Wald, A., Ewell, 
M. G., ... & Belshe, R. B. (2013). Epidemiology, clinical presentation, and antibody 
response to primary infection with herpes simplex virus type 1 and type 2 in young 
women. Clinical Infectious Diseases, 56(3), 344-351. 
Bradshaw, M. J., &Venkatesan, A. (2016). Herpes simplex virus-1 encephalitis in 
adults: pathophysiology, diagnosis, and management. Neurotherapeutics, 13(3), 493-508. 
Calland, N., Albecka, A., Belouzard, S., Wychowski, C., Duverlie, G., Descamps, 
V., ... & Séron, K. (2012). (−)‐Epigallocatechin‐3‐gallate is a new inhibitor of hepatitis C 
virus entry. Hepatology, 55(3), 720-729. 
36 
 
Campadelli‐Fiume, G., Amasio, M., Avitabile, E., Cerretani, A., Forghieri, C., 
Gianni, T., & Menotti, L. (2007). The multipartite system that mediates entry of herpes 
simplex virus into the cell. Reviews in medical virology, 17(5), 313-326. 
Cardone, G., Winkler, D. C., Trus, B. L., Cheng, N., Heuser, J. E., Newcomb, W. 
W., ... & Steven, A. C. (2007). Visualization of the herpes simplex virus portal in situ by 
cryo-electron tomography. Virology, 361(2), 426-434. 
Chitra, M., Shyamala Devi, C. S., & Sukumar, E. (2003). Antibacterial activity of 
Embelin. Fitoterapia, 74(4), 401-403. 
Chitra, M., Sukumar, E., Suja, V., & Devi, S. (1994). Antitumor, anti-
inflammatory and analgesic property of Embelin, a plant product. Chemotherapy, 40(2), 
109-113. 
Clarke, R. W. (2015). Forces and structures of the herpes simplex virus (HSV) 
entry mechanism. ACS infectious diseases, 1(9), 403-415. 
Cohrs, R. J., Mehta, S. K., Schmid, D. S., Gilden, D. H., & Pierson, D. L. (2008). 
Asymptomatic reactivation and shed of infectious varicella zoster virus in astronauts. 
Journal of medical virology, 80(6), 1116-1122. 
De Oliveira, A., Adams, S. D., Lee, L. H., Murray, S. R., Hsu, S. D., Hammond, 
J. R., ... & Chu, T. C. (2013). Inhibition of herpes simplex virus type 1 with the modified 




Denes, C. E., Everett, R. D., & Diefenbach, R. J. (2020). Tour de Herpes: Cycling 
Through the Life and Biology of HSV-1. In Herpes Simplex Virus (pp. 1-30). Humana, 
New York, NY. 
Dobson, C. B., & Itzhaki, R. F. (1999). Herpes simplex virus type 1 and 
Alzheimer’s disease. Neurobiology of aging, 20(4), 457-465. 
Docherty, J. J., Fu, M. M., Hah, J. M., Sweet, T. J., Faith, S. A., & Booth, T. 
(2005). Effect of resveratrol on herpes simplex virus vaginal infection in the mouse. 
Antiviral research, 67(3), 155-162. 
Docherty, J. J., Smith, J. S., Fu, M. M., Stoner, T., & Booth, T. (2004). Effect of 
topically applied resveratrol on cutaneous herpes simplex virus infections in hairless 
mice. Antiviral research, 61(1), 19-26. 
Durukan, D., Fairley, C. K., Bradshaw, C. S., Read, T. R., Druce, J., Catton, M., 
... & Chow, E. P. (2019). Increasing proportion of herpes simplex virus type 1 among 
women and men diagnosed with first-episode anogenital herpes: a retrospective 
observational study over 14 years in Melbourne, Australia. Sexually transmitted 
infections, 95(4), 307-313. 
Farooq, A. V., & Shukla, D. (2012). Herpes simplex epithelial and stromal 
keratitis: an epidemiologic update. Survey of ophthalmology, 57(5), 448-462. 
Flamand, L., Lautenschlager, I., Krueger, G., & Ablashi, D. (Eds.). (2014). 




Flores, D. J., Lee, L. H., & Adams, S. D. (2016). Inhibition of curcumin-treated 
Herpes Simplex Virus 1 and 2 in Vero cells. Advances in Microbiology, 6(4), 276-287. 
Frobert, E., Burrel, S., Ducastelle-Lepretre, S., Billaud, G., Ader, F., Casalegno, J. 
S., ... & Morfin, F. (2014). Resistance of herpes simplex viruses to acyclovir: an update 
from a ten-year survey in France. Antiviral research, 111, 36-41. 
George, B. P., Schneider, E. B., & Venkatesan, A. (2014). Encephalitis 
hospitalization rates and inpatient mortality in the United States, 2000-2010. PloS one, 
9(9). 
Gnann, J. W., & Whitley, R. J. (2017). Herpes simplex encephalitis: an update. 
Current infectious disease reports, 19(3), 13. 
Granzow, H., Klupp, B. G., Fuchs, W., Veits, J., Osterrieder, N., & Mettenleiter, 
T. C. (2001). Egress of alphaherpesviruses: comparative ultrastructural study. Journal of 
virology, 75(8), 3675-3684. 
Gupta, S., Sanyal, S., & Kanwar, U. (1991). Effects of embelin, a male 
antifertility agent, on absorptive and digestive functions of rat intestine. Journal of 
ethnopharmacology, 33(3), 203-212. 
Halford, W. P., Gebhardt, B. M., & Carr, D. J. (1996). Mechanisms of herpes 
simplex virus type 1 reactivation. Journal of virology, 70(8), 5051-5060. 
39 
 
Harden, E. A., Falshaw, R., Carnachan, S. M., Kern, E. R., & Prichard, M. N. 
(2009). Virucidal activity of polysaccharide extracts from four algal species against 
herpes simplex virus. Antiviral research, 83(3), 282-289. 
Harvey, A. L., Edrada-Ebel, R., & Quinn, R. J. (2015). The re-emergence of 
natural products for drug discovery in the genomics era. Nature reviews drug discovery, 
14(2), 111-129. 
Hassan, S. T., Masarčíková, R., & Berchová, K. (2015). Bioactive natural 
products with anti‐herpes simplex virus properties. Journal of Pharmacy and 
Pharmacology, 67(10), 1325-1336. 
Heldwein, E. E., Lou, H., Bender, F. C., Cohen, G. H., Eisenberg, R. J., & 
Harrison, S. C. (2006). Crystal structure of glycoprotein B from herpes simplex virus 1. 
Science, 313(5784), 217-220. 
Hoshino, Y., Pesnicak, L., Dowdell, K. C., Burbelo, P. D., Knipe, D. M., Straus, 
S. E., & Cohen, J. I. (2009). Protection from Herpes Simplex Virus (HSV)–2 Infection 
with Replication-Defective HSV-2 or Glycoprotein D2 Vaccines in HSV-1–Seropositive 
and HSV-1–Seronegative Guinea Pigs. The Journal of infectious diseases, 200(7), 1088-
1095. 
Hossan, M. S., Fatima, A., Rahmatullah, M., Khoo, T. J., Nissapatorn, V., 
Galochkina, A. V., ... & Wiart, C. (2018). Antiviral activity of Embelia ribes Burm. f. 
against influenza virus in vitro. Archives of virology, 163(8), 2121-2131. 
40 
 
Houston, D. M., Bugert, J. J., Denyer, S. P., & Heard, C. M. (2017). Correction: 
Potentiated virucidal activity of pomegranate rind extract (PRE) and punicalagin against 
Herpes simplex virus (HSV) when co-administered with zinc (II) ions, and antiviral 
activity of PRE against HSV and aciclovir-resistant HSV. PloS one, 12(11), e0188609. 
Houston, D. M., Bugert, J. J., Denyer, S. P., & Heard, C. M. (2017). Correction: 
Potentiated virucidal activity of pomegranate rind extract (PRE) and punicalagin against 
Herpes simplex virus (HSV) when co-administered with zinc (II) ions, and antiviral 
activity of PRE against HSV and aciclovir-resistant HSV. PloS one, 12(11), e0188609. 
Hsu, S. (2015). Compounds derived from epigallocatechin-3-gallate (EGCG) as a 
novel approach to the prevention of viral infections. Inflammation & Allergy-Drug 
Targets (Formerly Current Drug Targets-Inflammation & Allergy), 14(1), 13-18. 
Hu, R., Zhu, K., Li, Y., Yao, K., Zhang, R., Wang, H., ... & Liu, Z. (2011). 
Embelin induces apoptosis through down-regulation of XIAP in human leukemia cells. 
Medical oncology, 28(4), 1584-1588. 
Huleihel, M., & Isanu, V. (2002). Anti-herpes simplex virus effect of an aqueous 
extract of propolis. The Israel Medical Association journal: IMAJ, 4(11 Suppl), 923-927. 
Isaacs, C. E., Xu, W., Merz, G., Hillier, S., Rohan, L., & Wen, G. Y. (2011). 
Digallate dimers of (−)-epigallocatechin gallate inactivate herpes simplex virus. 
Antimicrobial agents and chemotherapy, 55(12), 5646-5653. 
41 
 
Itzhaki, R. F., Lin, W. R., Shang, D., Wilcock, G. K., Faragher, B., & Jamieson, 
G. A. (1997). Herpes simplex virus type 1 in brain and risk of Alzheimer's disease. The 
Lancet, 349(9047), 241-244. 
James, S. H., & Prichard, M. N. (2014). Current and future therapies for herpes 
simplex virus infections: mechanism of action and drug resistance. Current opinion in 
virology, 8, 54-61. 
Ji, H. F., Li, X. J., & Zhang, H. Y. (2009). Natural products and drug discovery. 
EMBO reports, 10(3), 194-200. 
Joy, B., Sivadasan, R., Emilia, A. T., John, M., Sobhan, P. K., Seervi, M., & TR, 
S. (2010). Lysosomal destabilization and cathepsin B contributes for cytochrome c 
release and caspase activation in Embelin‐induced apoptosis. Molecular Carcinogenesis: 
Published in cooperation with the University of Texas MD Anderson Cancer Center, 
49(4), 324-336. 
Kumar, G. K., Dhamotharan, R., Kulkarni, N. M., Mahat, M. Y. A., Gunasekaran, 
J., & Ashfaque, M. (2011). Embelin reduces cutaneous TNF-α level and ameliorates skin 
edema in acute and chronic model of skin inflammation in mice. European journal of 
pharmacology, 662(1-3), 63-69. 
Kumar, S., & Deshmukh, R. (2017). Embelin as a potential drug molecule: a 
review. J Pharmacogn Nat Prod, 3(3), 1-7. 
42 
 
Kuo, T., Wang, C., Badakhshan, T., Chilukuri, S., & BenMohamed, L. (2014). 
The challenges and opportunities for the development of a T-cell epitope-based herpes 
simplex vaccine. Vaccine, 32(50), 6733-6745. 
Lasky, L. A., & Dowbenko, D. J. (1984). DNA sequence analysis of the type-
common glycoprotein-D genes of herpes simplex virus types 1 and 2. Dna, 3(1), 23-29. 
Lavoie, S., Côté, I., Pichette, A., Gauthier, C., Ouellet, M., Nagau-Lavoie, F., & 
Legault, J. (2017). Chemical composition and anti-herpes simplex virus type 1 (HSV-1) 
activity of extracts from Cornus canadensis. BMC complementary and alternative 
medicine, 17(1), 123. 
Letenneur, L., Pérès, K., Fleury, H., Garrigue, I., Barberger-Gateau, P., Helmer, 
C., ... & Dartigues, J. F. (2008). Seropositivity to herpes simplex virus antibodies and risk 
of Alzheimer's disease: a population-based cohort study. PloS one, 3(11). 
Li, G., Guo, J., Wang, Z., Liu, Y., Song, H., & Wang, Q. (2018). Marine natural 
products for drug discovery: first discovery of kealiinines A–C and their derivatives as 
novel antiviral and antiphytopathogenic fungus agents. Journal of agricultural and food 
chemistry, 66(28), 7310-7318. 
Liang, H., Gao, D., Yu, W., Chen, C., Deng, Y., Lei, Y., ... & Xiong, S. (2018). 
Antiviral Activity and its Mechanism of LCVN Against HSV-1 Acyclovir-resistant 
Strains. Journal of Pharmaceutical and Biomedical Sciences, 8(3). 
43 
 
Linakis, S., & Reynolds, M. (2020). Disseminated Neonatal Herpes Simplex 
Virus: Simplex Can Be Very Complex! In Case Studies in Emergency Medicine (pp. 
175-181). Springer, Cham. 
Looker, K. J., Magaret, A. S., May, M. T., Turner, K. M., Vickerman, P., 
Newman, L. M., & Gottlieb, S. L. (2017). First estimates of the global and regional 
incidence of neonatal herpes infection. The Lancet Global Health, 5(3), e300-e309. 
Looker, K. J., Magaret, A. S., May, M. T., Turner, K. M., Vickerman, P., 
Gottlieb, S. L., & Newman, L. M. (2015). Global and regional estimates of prevalent and 
incident herpes simplex virus type 1 infections in 2012. PloS one, 10(10). 
Mahant, S., Hall, M., Schondelmeyer, A. C., Berry, J. G., Kimberlin, D. W., Shah, 
S. S., ... & Collaborative Antiviral Study Group. (2019). Neonatal herpes simplex virus 
infection among Medicaid-enrolled children: 2009–2015. Pediatrics, 143(4), e20183233. 
Mahendran, S., Badami, S., & Maithili, V. (2011). Evaluation of antidiabetic 
effect of Embelin from Embelia ribes in alloxan induced diabetes in rats. Biomedicine & 
Preventive Nutrition, 1(1), 25-31. 
McGeoch, D. J., Dalrymple, M. A., Davison, A. J., Dolan, A., Frame, M. C., 
McNab, D., ... & Taylor, P. (1988). The complete DNA sequence of the long unique 
region in the genome of herpes simplex virus type 1. Journal of General Virology, 69(7), 
1531-1574. 
McGeoch, D. J., Rixon, F. J., & Davison, A. J. (2006). Topics in herpesvirus 
genomics and evolution. Virus research, 117(1), 90-104. 
44 
 
McGrath, N., Anderson, N. E., Croxson, M. C., & Powell, K. F. (1997). Herpes 
simplex encephalitis treated with acyclovir: diagnosis and long-term outcome. Journal of 
Neurology, Neurosurgery & Psychiatry, 63(3), 321-326. 
McQuillan, G. M., Kruszon-Moran, D., Flagg, E. W., & Paulose-Ram, R. (2018). 
Prevalence of herpes simplex virus type 1 and type 2 in persons aged 14-49: United 
States, 2015-2016 (pp. 1-8). US Department of Health and Human Services, Centers for 
Disease Control and Prevention, National Center for Health Statistics. 
Mettenleiter, T. C., Klupp, B. G., & Granzow, H. (2006). Herpesvirus assembly: a 
tale of two membranes. Current opinion in microbiology, 9(4), 423-429. 
Mettenleiter, T. C., & Sobrino, F. (Eds.). (2008). Animal viruses: molecular 
biology (Vol. 1). Norfolk: Caister Academic Press. 
Middleton, P., Petric, M., Kozak, M., Rewcastle, N. B., & McLachlan, D. C. 
(1980). Herpes-simplex viral genome and senile and presenile dementias of Alzheimer 
and Pick. The Lancet, 315(8176), 1038. 
Mosmann, J. P., Talavera, A. D., Criscuolo, M. I., Venezuela, R. F., Kiguen, A. 
X., Panico, R., ... & Cuffini, C. G. (2019). Sexually transmitted infections in oral cavity 
lesions: Human papillomavirus, Chlamydia trachomatis, and Herpes simplex virus. 
Journal of oral microbiology, 11(1), 1632129. 
Murphy, E., Vaníček, J., Robins, H., Shenk, T., & Levine, A. J. (2008). 
Suppression of immediate-early viral gene expression by herpesvirus-coded microRNAs: 
45 
 
implications for latency. Proceedings of the National Academy of Sciences, 105(14), 
5453-5458. 
Newcomb, W. W., Booy, F. P., & Brown, J. C. (2007). Uncoating the herpes 
simplex virus genome. Journal of molecular biology, 370(4), 633-642. 
Nguyen, L. H., Knipe, D. M., & Finberg, R. W. (1992). Replication-defective 
mutants of herpes simplex virus (HSV) induce cellular immunity and protect against 
lethal HSV infection. Journal of virology, 66(12), 7067-7072. 
Parvez, M. K., Rehman, M. T., Alam, P., Al-Dosari, M. S., Alqasoumi, S. I., & 
Alajmi, M. F. (2019). Plant-derived antiviral drugs as novel hepatitis B virus inhibitors: 
Cell culture and molecular docking study. Saudi Pharmaceutical Journal, 27(3), 389-400. 
Paschalis, V. (2019). Inhibition of HSV-1 Binding by EGCG-Stearate. 
Unpublished Master’s thesis. Montclair State University, Montclair, NJ. 
Piret, J., & Boivin, G. (2011). Resistance of herpes simplex viruses to nucleoside 
analogues: mechanisms, prevalence, and management. Antimicrobial agents and 
chemotherapy, 55(2), 459-472. 
Placek, B. J., & Berger, S. L. (2010). Chromatin dynamics during herpes simplex 
virus-1 lytic infection. Biochimica et Biophysica Acta (BBA)-Gene Regulatory 
Mechanisms, 1799(3-4), 223-227. 
Poojari, R. (2014). Embelin–a drug of antiquity: shifting the paradigm towards 
modern medicine. Expert opinion on investigational drugs, 23(3), 427-444. 
46 
 
Pradeep, P., Manju, V., & Ahsan, M. F. (2019). Antiviral Potency of Mushroom 
Constituents. In Medicinal Mushrooms (pp. 275-297). Springer, Singapore. 
Prakash, A. O. (1994). Short term toxicity of embelin in female rats. Phytotherapy 
Research, 8(5), 257-264. 
Pullaiah, T. (2002). Medicinal Plants in India, Vol. 1. New Delhi: Regency 
Publication. 
Radhakrishnan, N., & Gnanamani, A. (2014). 2, 5-dihydroxy-3-undecyl-1, 4-
benzoquinone (Embelin)-A second solid gold of India-A Review. International Journal 
Pharmacy & Pharmaceutical Sciences, 6(6), 23-30. 
Radhakrishnan, N., & Gnanamani, A. (2014). 2, 5-dihydroxy-3-undecyl-1, 4-
benzoquinone (Embelin)-A second solid gold of India-A Review. International Journal 
Pharmacy & Pharmaceutical Sciences, 6(6), 23-30. 
Radhakrishnan, N., Gnanamani, A., & Mandal, A. B. (2011). A potential 
antibacterial agent Embelin, a natural benzoquinone extracted from Embelia ribes. 
Biology and medicine, 3(2), 1-7. 
Rajčáni, J., Andrea, V., & Ingeborg, R. (2004). Peculiarities of herpes simplex 
virus (HSV) transcription: an overview. Virus genes, 28(3), 293-310. 
Royer, D. J., Cohen, A. W., & Carr, D. J. (2015). The current state of vaccine 




Sandgren, K. J., Bertram, K., & Cunningham, A. L. (2016). Understanding natural 
herpes simplex virus immunity to inform next‐generation vaccine design. Clinical & 
translational immunology, 5(7), e94. 
Schnitzler, P., Neuner, A., Nolkemper, S., Zundel, C., Nowack, H., Sensch, K. H., 
& Reichling, J. (2010). Antiviral activity and mode of action of propolis extracts and 
selected compounds. Phytotherapy Research, 24(S1), S20-S28. 
Shukla, D., & Spear, P. G. (2001). Herpesviruses and heparan sulfate: an intimate 
relationship in aid of viral entry. The Journal of clinical investigation, 108(4), 503-510. 
Shukla, D., Tiwari, V., Clement, C., Scanlan, P. M., & Liu, J. (2004). Role of 3–
O–Sulfated Heparan Sulfate in Herpes Simplex Virus Type–1 Entry and Spread. 
Investigative Ophthalmology & Visual Science, 45(13), 1647-1647. 
Sievers, E., Neumann, J., Raftery, M., SchÖnrich, G., Eis‐Hübinger, A. M., & 
Koch, N. (2002). Glycoprotein B from strain 17 of herpes simplex virus type I contains 
an invariant chain homologous sequence that binds to MHC class II molecules. 
Immunology, 107(1), 129-135. 
Singh, D., Singh, R., Singh, P., & Gupta, R. S. (2009). Effects of Embelin on lipid 
peroxidation and free radical scavenging activity against liver damage in rats. Basic & 
clinical pharmacology & toxicology, 105(4), 243-248. 
Sodeik, Beate, Melanie W. Ebersold, and Ari Helenius. "Microtubule-mediated 
transport of incoming herpes simplex virus 1 capsids to the nucleus." The Journal of cell 
biology 136.5 (1997): 1007-1021. 
48 
 
Spear, Patricia G. "Herpes simplex virus: receptors and ligands for cell entry." 
Cellular microbiology 6.5 (2004): 401-410. 
Su, C., Zhan, G., & Zheng, C. (2016). Evasion of host antiviral innate immunity 
by HSV-1, an update. Virology journal, 13(1), 38.. 
Subramanian, Ravi P., & Robert J. Geraghty. "Herpes simplex virus type 1 
mediates fusion through a hemifusion intermediate by sequential activity of glycoproteins 
D, H, L, and B." Proceedings of the National Academy of Sciences104.8 (2007): 2903-
2908. 
Szpara, M. L., Gatherer, D., Ochoa, A., Greenbaum, B., Dolan, A., Bowden, R. J., 
... & Davison, A. J. (2014). Evolution and diversity in human herpes simplex virus 
genomes. Journal of virology, 88(2), 1209-1227. 
Tiwari, V., & Shukla, D. (2010). Phosphoinositide 3 kinase signalling may affect 
multiple steps during herpes simplex virus type-1 entry. The Journal of general virology, 
91(Pt 12), 3002. 
Tyring, S. K., Beutner, K. R., Tucker, B. A., Anderson, W. C., & Crooks, R. J. 
(2000). Antiviral therapy for herpes zoster: randomized, controlled clinical trial of 
valacyclovir and famciclovir therapy in immunocompetent patients 50 years and older. 
Archives of family medicine, 9(9), 863. 
Tzeng, N. S., Chung, C. H., Lin, F. H., Chiang, C. P., Yeh, C. B., Huang, S. Y., ... 
& Chiang, W. S. (2018). Anti-herpetic medications and reduced risk of dementia in 
49 
 
patients with herpes simplex virus infections—a nationwide, population-based cohort 
study in Taiwan. Neurotherapeutics, 15(2), 417-429. 
Vázquez, L., Corzo-Martínez, M., Arranz-Martínez, P., Barroso, E., Reglero, G., 
& Torres, C. (2018). Bioactive Lipids. Bioactive Molecules in Food, 1-61. 
Vázquez-Calvo, Á., Jiménez de Oya, N., Martín-Acebes, M. A., Garcia-Moruno, 
E., & Saiz, J. C. (2017). Antiviral properties of the natural polyphenols delphinidin and 
epigallocatechin gallate against the flaviviruses West Nile virus, Zika virus, and dengue 
virus. Frontiers in microbiology, 8, 1314. 
Whitley, Richard J., & Bernard Roizman. "Herpes simplex virus infections." The Lancet 
357.9267 (2001): 1513-1518. 
Willard, M. (2002). Rapid directional translocations in virus replication. Journal 
of virology, 76(10), 5220-5232. 
Wolfram, S. (2007). Effects of green tea and EGCG on cardiovascular and 
metabolic health. Journal of the American College of Nutrition, 26(4), 373S-388S. 
Wozniak, M. A., Frost, A. L., Preston, C. M., & Itzhaki, R. F. (2011). Antivirals 
reduce the formation of key Alzheimer's disease molecules in cell cultures acutely 
infected with herpes simplex virus type 1. PLoS One, 6(10). 
Xu, M., Cui, J., Fu, H., Proksch, P., Lin, W., & Li, M. (2005). Embelin 




Zandi, K., Ramedani, E., Mohammadi, K., Tajbakhsh, S., Deilami, I., Rastian, Z., 
... & Farshadpour, F. (2010). Evaluation of antiviral activities of curcumin derivatives 
against HSV-1 in Vero cell line. Natural product communications, 5(12), 
1934578X1000501220. 
Zandi, K., Ramedani, E., Mohammadi, K., Tajbakhsh, S., Deilami, I., Rastian, Z., 
... & Farshadpour, F. (2010). Evaluation of antiviral activities of curcumin derivatives 
against HSV-1 in Vero cell line. Natural product communications, 5(12), 
1934578X1000501220. 
Zatońksi, W. 1: Jha P, Chaloupka FJ, Moore J, Gajalakshmi V, Gupta PC, Peck R, 
Asma S, Zatonski W. Tobacco Addiction. In: Jamison DT, Breman JG, Measham AR, 
Alleyne G, Claeson M, Evans DB, Jha P, Mills A, Musgrove P, editors. Disease Control 
Priorities in Developing Countries. Washington (DC): World Bank; 2006. Chapter 46. 
 
